Truist raised the firm’s price target on Gilead (GILD) to $152 from $145 and keeps a Buy rating on the shares. The company delivered Q4 top- and bottom-line beats, driven primarily by continued strength of the HIV franchise, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Underappreciated Earnings Power: Why Strong HIV Momentum and Margin Expansion Support a Buy on Gilead
- Gilead Sciences: HIV Franchise Strength, Yeztugo Ramp, and Solid 2026 Outlook Underpin Buy Rating and Positive Risk‑Reward
- Reaffirming Gilead as a Buy: Conservative 2026 Guidance, Beatable Yeztugo Outlook, and Durable HIV-Driven Growth
- Gilead price target raised to $145 from $108 at Baird
- Gilead price target raised to $160 from $150 at BMO Capital